Semaglutide Weight Management and Cardiovascular Risk Reduction
Mean weight loss was -15.6% and more than half of patients
achieved ≥15% weight loss when treated with CagriSema
Higher body weight reduction with CagriSema compared to semaglutide
and cagrilintide alone
Mean baseline body weight: 105.7 kg
Change in body weight (%)
-12
ထ
+
-5.1
-8.1
-15.6
-16
0
4
8 12
16
20
20
28
32
2
Time since randomisation (weeks)
CagriSema Semaglutide Cagrilintide
% of patients
Categorical weight loss after 32 weeks of treatment
100
75
50
71.4%
25
23.3%
25
13.8%
CagriSema Sema
≥10% body weight
reduction
Note: Data shown on weight loss over time is trial product estimands. Data on categorical weight loss is from post-hoc analysis (descriptive), from the on-treatment period.
Note: CagriSema is a fixed dose combination of injectable cagrilintide 2.4 mg and injectable semaglutide 2.4 mg. Sema: Semaglutide; Cagri: Cagrilintide
53.6%
6.7%
0%
Cagri
CagriSema Semal
Cagri
≥ 15% body weight
reductionView entire presentation